
    
      This is a phase II, open label, partially randomized, three treatment group study designed to
      evaluate the steady state pharmacokinetics of buprenorphine and norbuprenorphine following
      repeated subcutaneous administrations of CAM2038 weekly and monthly at different injection
      sites and to evaluate the steady state pharmacokinetics of buprenorphine and norbuprenorphine
      after repeated subcutaneous administration of CAM2038 monthly in opioid dependent subjects
      with a history of chronic non cancer pain. The study will involve three phases: Screening,
      Treatment, and Follow up.
    
  